|
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and . . .
AI builds upon digital pathology by identifying patterns in a digitized image that suggest cancer or other diseases, helping a pathologist concentrate on areas of concern for potentially more accurate diagnosis Quest has a long history of strategic AI and automation deployment
- Quest Diagnostics Newsroom - News Releases
The company has successfully deployed AI and automation in several areas of its organization, including microbiology and cytology testing, specimen processing and customer service
- Q3 CS | Quest Diagnostics
Powerful tools to assist pathologists, including artificial intelligence (AI) algorithms that enable automated image analysis for qualification and quantification of tissue samples, aiding in the precision and grading of the final diagnosis
- Autoimmune Test Portfolio Overview - Quest Diagnostics
Over 150 tests and panels to screen, diagnose, and monitor autoimmune disease From comprehensive panels to single biomarkers, our specialty autoimmune (AI) test menu, including those tests featured below, can help you diagnose and monitor 80+ AI diseases
- Quest Diagnostics Extends Alzheimers Disease Portfolio with New AI . . .
The RestoreU service employs artificial intelligence (AI) developed by uMETHOD to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines*
- Pathology in the era of precision medicine - Quest Diagnostics
In the arena of digital pathology, AmeriPath, under Quest Diagnostics, has been proactive in harnessing the capabilities of AI to foster advancements in diagnostic accuracy and speed
- Sm and Sm RNP Antibodies | Test Detail | Quest Diagnostics
Clinical Significance Sm and Sm RNP Antibodies - Antibodies to Sm are highly specific for systemic lupus erythematosus (SLE) and when present are considered a marker antibody However, these antibodies are found in only 20% of patients with SLE RNP antibodies (also known as anti-u1 or ribonucleoprotein antibodies) are found in 45% of SLE patients but are also observed in numerous other
|
|
|